Why the study?
Balancing antithrombotic therapy to prevent ischemic events while minimizing bleeding remains a clinical challenge for AF patients undergoing PCI due to coexisting thrombogenic risks.
Does NOAC-based double antithrombotic therapy reduce bleeding complications compared to triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention?
Does NOAC-based double antithrombotic therapy reduce bleeding complications compared to triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention?
Answers are grounded in this paper and cite their sources.
NOAC-based double antithrombotic therapy offers a more favorable safety profile than triple therapy by reducing major bleeding without compromising ischemic efficacy in AF patients undergoing PCI.
INTRODUCTION: Balancing antithrombotic therapy for atrial fibrillation (AF) patients undergoing percutaneous coronary intervention (PCI) remains a clinical challenge due to coexisting thrombogenic risks. This review emphasizes the delicate balance required to prevent ischemic events while minimizing bleeding complications, particularly in the context of risk assessment. AREAS COVERED: This review spans from 2010 to October 2023, exploring the complexities of antithrombotic management for AF patients undergoing PCI. It stresses the need for personalized treatment decisions to optimize antithrombotic therapies effectively. EXPERT OPINION: The evolving evidence supports double antithrombotic therapy (DAT) over triple antithrombotic therapy (TAT) for these patients, showcasing a more favorable safety profile without compromising efficacy. Non-vitamin K antagonist oral anticoagulant (NOAC)-based DAT strategies exhibit superiority in reducing major bleeding events while effectively preventing ischemic events. Recommendations from the 2023 European Society of Cardiology (ESC) Guidelines advocate for NOAC-based DAT post-PCI, endorsing safer antithrombotic profiles.Challenges persist for specific patient categories requiring both oral anticoagulants and antiplatelets, necessitating personalized approaches. Future advances in intravascular imaging and novel coronary stent technologies offer promising avenues to optimize outcomes and influence antithrombotic strategies in AF-PCI patients.
No takes yet. Share an insight, caveat, or question.
Erbay et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: